Roche Invirase/Hivid combo reduces mortality by 68% compared to Hivid alone.
Executive Summary
ROCHE INVIRASE/HIVID COMBO REDUCES AIDS MORTALITY 68% compared to Hivid (zalcitabine, ddC) alone, according to the findings of the NV14256 study released by Roche May 7. There were 34 deaths in patients treated with the protease inhibitor Invirase (saquinavir) alone and 28 for ddC alone, compared to nine for saquinavir plus ddC.